We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
340.85%
This Fund
S&P 500
This Quarter
Est. Return
+8.25%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
(+25%)
Cap. Flow
+$320M
Cap. Flow
% of AUM
18.81%
Top 10 Holdings %
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
+$40.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.1M |
| 3 |
Denali Therapeutics
DNLI
|
+$36.2M |
| 4 |
Inspire Medical Systems
INSP
|
+$27.3M |
| 5 |
Vir Biotechnology
VIR
|
+$21.9M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$39.4M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$17.3M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$13.2M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$10.4M |
| 5 |
Arbutus Biopharma
ABUS
|
+$9.98M |
Sector Composition
| 1 | Healthcare | 88.42% |
| 2 | Financials | 1.51% |
| 3 | Technology | 0.08% |
| 4 | Industrials | 0.08% |
| 5 | Materials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Evolus
EOLS
$381M
| $230K | 0.01% |
55,859
+20,000
| +56% | +$96.9K |
|
252
Q32 Bio
QTTB
$256M
| $225K | 0.01% |
35,000
+15,000
| +75% | +$71.3K |
|
|
LGVN
253
Longeveron
LGVN
$19.6M
| $208K | 0.01% |
+200,000
| New | +$132K |
|
254
AnaptysBio
ANAB
$1.62B
| $205K | 0.01% |
+3,698
| New | +$199K |
|
|
CEPS
255
Cantor Equity Partners VI
CEPS
$153M
| $202K | 0.01% |
+20,000
| New | +$202K |
|
|
KALV
256
DELISTED
KalVista Pharmaceuticals
KALV
| $201K | 0.01% |
10,000
| – | – |
|
257
Kyverna Therapeutics
KYTX
$451M
| $194K | 0.01% |
22,428
-35,000
| -61% | -$292K |
|
258
Nuvation Bio
NUVB
$2.01B
| $187K | 0.01% |
+43,500
| New | +$242K |
|
259
Benitec Biopharma
BNTC
$442M
| $186K | 0.01% |
+17,500
| New | +$203K |
|
260
Lipocine
LPCN
$19.1M
| $185K | 0.01% |
+23,180
| New | +$202K |
|
261
Rallybio
RLYB
$92.9M
| $184K | 0.01% |
+20,535
| New | +$140K |
|
262
Rezolute
RZLT
$427M
| $179K | 0.01% |
58,679
+20,000
| +52% | +$60K |
|
|
QCLS
263
Q/C Technologies Inc
QCLS
$26.2M
| $173K | 0.01% |
+50,000
| New | +$203K |
|
264
Erasca
ERAS
$6.21B
| $162K | 0.01% |
+10,000
| New | +$118K |
|
265
Coya Therapeutics
COYA
$109M
| $161K | 0.01% |
+40,900
| New | +$191K |
|
266
Personalis
PSNL
$1.56B
| $159K | 0.01% |
+25,000
| New | +$211K |
|
267
SI-BONE Inc
SIBN
$793M
| $159K | 0.01% |
+12,580
| New | +$197K |
|
268
The Oncology Institute
TOI
$548M
| $154K | 0.01% |
+50,000
| New | +$153K |
|
|
HELP
269
Cybin Inc
HELP
$448M
| $150K | 0.01% |
31,278
-207,112
| -87% | -$1.34M |
|
270
Neuronetics
STIM
$134M
| $145K | 0.01% |
+100,000
| New | +$159K |
|
271
Ardelyx
ARDX
$1.27B
| $143K | 0.01% |
+23,900
| New | +$158K |
|
272
InflaRx
IFRX
$292M
| $142K | 0.01% |
+158,271
| New | +$150K |
|
273
Achieve Life Sciences
ACHV
$615M
| $141K | 0.01% |
47,800
| – | – |
|
274
Voyager Therapeutics
VYGR
$186M
| $135K | 0.01% |
35,000
| – | – |
|
|
CMMB
275
Chemomab Therapeutics
CMMB
$11.1M
| $126K | 0.01% |
80,000
| – | – |
|
Similar funds
RSCM
AAM
SGI
WAS
BCM
SWM
TCM
ISS